

MINUTES OF BOARD MEETING

Held on September 23, 2025 | 12:00 pm to 1:00 pm
Videoconference

Chair:	Claire Ramlogan-Salanga, RM
Present:	Lynne-Marie Culliton, RM; Abir Hoblos, RM; Marianna Kaminska; Isabelle Milot, RM; Christopher Panos; Maryam Rahimi-Chatrri, RM; Alexia Singh, RM; Don Strickland
Regrets:	Judith Murray; Jyothy Nair, RM; Edan Thomas, RM; Tina Walia-Rao
Staff:	Kelly Dobbin, Nadja Gale, Emma Hosein, Megan McCarrell
Observers:	Deborah Bonser (AOM); Abigail Duncan (MOH)
Recorder:	Emma Hosein

1. Call to Order: Welcome and Land Acknowledgement

Claire Ramlogan-Salanga, Chair, called the meeting to order at 12:03 pm and welcomed all present. The Chair then shared a land acknowledgement to open.

2. Declaration of Conflict of Interests

No conflicts of interest were declared.

3. Proposed Agenda

MOTION: That the proposed agenda be approved as presented.

Moved: Tina Walia-Rao

Seconded: Alexia Singh

CARRIED

4. Designated Drugs and Substances Regulation

Megan McCarrell, Director of Professional Practice, presented the briefing materials for this item which were included as part of the meeting materials. The Board was walked through the process that has resulted in the proposed addition of the RSV monoclonal antibody to the College's Designated Drugs and Substances Regulation to improve access to care during the upcoming RSV season. This regulatory amendment will enable midwives to provide the National Advisory Committee on Immunizations (NACI) recommended RSV immunization to newborns, addressing a current gap in the Regulation schedules. The

College received 81 responses to the 60-day public consultation on the proposed amendment, which closed on August 26, 2025. No negative feedback was reported, and letters of support were received from both the Association of Ontario Midwives and the Ontario Medical Association.

Staff reported that the Ministry of Health remains engaged and supportive, identifying this regulation change as a priority to improve public health access. While formal confirmation is pending, there is optimism that the regulation will be finalized in time for the 2025–2026 RSV season.

Board members underscored that the amendment reflects regulatory responsiveness and the College’s commitment to advancing equitable access to care. Members recognized the importance of authorizing midwives to deliver RSV immunization as part of integrated maternal and newborn care, with Claire Ramlogan-Salanga noting the change is both timely and long overdue. The Board expressed appreciation to Megan McCarrell, her team, and College staff for their diligence in advancing this work. The College will now submit the approved amendment to the Ministry of Health and prepare for implementation, pending final approval.

MOTION: That the Board approve the addition of “RSV monoclonal antibody” to Schedules 1 and 3 of Vaccines and Immune Globulins in the Designated Drugs and Substances Regulation O. Reg. 188/24 for final submission to the Ministry of Health.

In Favour: Lynne-Marie Culliton (RM), Abir Hoblos (RM), Marianna Kaminska, Isabelle Milot (RM), Christopher Panos, Maryam Rahimi-Chatri (RM), Claire Ramlogan-Salanga (RM), Alexia Singh (RM), Donald Strickland

Opposed: None

Abstained: None

MOTION CARRIED

5. HOUSEKEEPING

The remaining 2025-2026 Board and committee training & Board meeting dates are as follows:

November 4-5, 2025 (via videoconference)
February 24, 2026 (via videoconference)

6. ADJOURNMENT

MOTION: That the meeting be adjourned at 12:19 pm.

Moved: Lynne-Maire Culliton
Seconded: Alexia Singh
CARRIED